Abciximab in acute ischemic stroke: A randomized, double-blind, placebo-controlled, dose-escalation study

Stroke

Volumn 31, Issue 3, 2000, Pages 601-609

  Adams Jr , H P ^a   Bogousslavsky, Julien ^b  

^a UNIVERSITY OF IOWA   (United States)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Platelet aggregation inhibitors; Randomized controlled trials; Stroke, ischemic

Indexed keywords

ABCIXIMAB; FIBRINOGEN RECEPTOR ANTAGONIST;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RADIODIAGNOSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0342514814     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.str.31.3.601     Document Type: Article

References (32)

1. The National Institute of Neurological Disorders, and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
2. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, Boysen G, Bluhmki E, Hoxter G, Mahagne MH, Hennerici M, for the ECASS Study Group. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. JAMA. 1995;274:1017-1025.
3. The NINDS t-PA Stroke Study Group. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke. 1997;28:2109-2118.
4. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, Schneider D, Diez-Tejedor E, Trouillas P, for the Second European-Australasian Acute Stroke Study Investigators. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet. 1998;352:1245-1251.
5. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S, for the ATLANTIS Study Investigators. Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset: the ATLANTIS study: a randomized controlled trial. JAMA. 1999; 282:2019-2026.
6. Sandercock PAG, van den Belt AGM, Lindley RI, Slattery J. Antithrombotic therapy of acute ischemic stroke: an overview of the completed randomized trials. J Neurol Neurosurg Psychiatry. 1993;56:17-25.
7. Sandercock P, for the International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomized trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischemic stroke. Lancet. 1997;349:1569-1581.
8. The Publication Committee for the Trial of ORG 1072 in Acute Stroke Treatment (TOAST) Investigators. Low molecular weight heparinoid ORG 1072 (Danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. JAMA. 1998;279:1265-1272.
9. CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomised placebo-controlled trial of early aspirin use in 20 000 patients with acute ischemic stroke. Lancet. 1997;349:1641-1649.
10. Chong PH. Glycoprotein IIb/IIIa antagonists in the management of cardiovascular diseases. Am J Health Syst Pharm. 1998;55:2363-2386.
11. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994;330:956-961.
12. The EPILOG Investigators. Effect of the platelet glycoprotein Ilb/IIIa receptor inhibitor abciximab with lower heparin dosages in ischemic complications of percutaneous coronary revascularization. N Engl J Med. 1997; 336:1689-1696.
13. The CAPTURE Investigators. Refractory unstable angina reduction of events by treatment with abciximab prior to coronary intervention. Lancet. 1997; 349:1429-1435.
14. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet. 1998;352:87-92.
15. Tcheng JE, Ellis SG, George BS, Kereiakis DJ, Kleiman NS, Talley D, Wang AL, Weisman HF, Califf RM. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation. 1994;90:1757-1764.
16. Mascelli MA, Lance ET, Damajaru L, Wagner CL, Weisman HF, Jordan RE. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Circulation. 1998;97:1680-1688.
17. 3 integrins. Circulation. 1998;141:1085-1091.
18. Altieri D, Edgington TS. A monoclonal antibody reacting with distinct adhesion molecules defines a transition in the functional state of the receptor CD11b/CD18 (Mac-1). J Immunol. 1998;141:2656-2660.
19. Antman EM, Giugliano RP, Gibson CM, McCabe CH, Coussement P, Kleiman NS, Vahanian A, Adgey AAJ, Menown I, Rupprecht HJ, van der Wieken R, Ducas J, Scherer J, Anderson K, van de Werf F, Braunwald E, for the TIMI 14 Investigators. Abciximab facilitates the rate and extent of thrombolysis: results of the Thrombolysis in Myocardial Infarction (TIMI) 14 Trial. Circulation. 1999;99:2720-2732.
20. Ohman EM, Lincolff AM, Bode C, Bachinsky WB, Ardissino D, Betriu A, Schildcrout JS. Enhanced early reperfusion at 60 minutes with low-does retaplase combined with full-dose abciximab in acute myocardial infarction: preliminary results from the GUSTO-4 Pilot (SPEED) dose-ranging trial. Circulation. 1998;98(suppl I):I-504. Abstract.
21. van den Merkhof LFM, Zijlstra F, Olsson H, Grip L, Veen G, Bar FWHM, van den Brand MJBM, Simoons ML, Verbeugt FWA. Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty. J Am Coll Cardiol. 1999;33:1528-1532.
22. Neumann FJ, Blasini R, Schmitt C, Alt E, Dirschinger J, Gawaz M, Kastrati A, Schomig A. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after placement of coronary-artery stents in acute myocardial infarction. Circulation. 1998;98:2695-2701.
23. Kaku S, Umemura K, Mizuno A, Yano S, Suzuki H, Kawasaki T, Nakashima M. Evaluation of a GPIIb/IIIa antagonist YM337 in a primate model of middle cerebral artery thrombosis. Eur J Pharmacol. 1998;345:185-192.
24. Choudri TF, Hoh BL, Zerwes HG, Prestigiacomo CJ, Kim SC, Connolly ES, Kottirsch G, Pinsky DJ. Reduced microvascular thrombosis and improved outcome in acute murine stroke by inhibiting GP IIb/IIIa receptor-mediated platelet aggregation. J Clin Invest. 1998;102:1301-1310.
25. Wallace RC, Furlan AJ, Moliterno DJ, Stevens GHJ, Masaryk TJ, Perl J II. Basilar artery rethrombosis: successful treatment with platelet glycoprotein IIb/IIIa receptor inhibitor. Am J Neuroradiol. 1997;18:1257-1260.
26. Cecena FA, Hoelzinger DH, Miller JA, Abu-Shakra S. The platelet IIb/IIIa inhibitor abciximab as adjunctive therapy in carotid stenting of potential thrombotic lesions. J Intervent Cardiol. 1999;12:355-361.
27. Brott T, Adams H Jr, Olinger CP, Marier JR, Barsan WG, Biller J, Spilker J, Holleran R, Eberle R, Hertzberg V, Rorick M, Moomaw CJ, Walker M. Measurements of acute cerebral infarction: a clinical examination scale. Stroke. 1989;20:864-870.
28. Mahoney FI, Barthel DW. Functional evaluation: the BI. Md State Med J. 1965;14:61-65.
29. Rankin J. Cerebral vascular accidents in people over the age of 60, II: prognosis. Scott Med J. 1957;2:200-215.
30. Rao AK, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber TL, Bell WR, Knatterud G, Robertson TL, Terrin ML, for the TIMI Investigators. Thrombolysis in myocardial infarction (TIMI) trial - phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol. 1988;11:1-11.
31. The NINDS t-PA Stroke Study group. Intracerebral hemorrhage after intravenous t-PA therapy for acute ischemic stroke. Stroke. 1997;28:2109-2118.
32. Christopoulos CG, Machin SJ. A new type of pseudothrombocytopenia: EDTA-mediated agglutination of platelets bearing Fab fragments of a chimaeric antibody. Br J Haematol. 1994;87:650-652.